Given the critical role of the PI3K/Akt/mTOR pathway in OSCC pathogenesis and its contribution to the aggressive characteristics of the tumor, targeting this pathway offers a strategic approach to cancer therapy. This evidence concerns the gene MTOR and neoplasm.